Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965452 · ClinicalTrials.gov registry record · NA
Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy
A NA study of Pain and Osteoarthritis, sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06965452: Recruiting NA study of Pain and Osteoarthritis, sponsored by Northwell Health.
NCT06965452 is a NA study of Pain and Osteoarthritis that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 40 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06965452, a NA study of Pain and Osteoarthritis, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
Primary Outcome
The primary outcome measurements for safety are: -The number of procedure-related serious adverse events occurring in the perioperative period
Conditions Studied
Interventions
- DEVICE Spinal angiography and embolization/ Embozene Microspheres
Study Locations (1)
New York
- North Shore University Hospital - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2026-08-01 |
| Phase | NA |
What NCT06965452 shows while recruiting
NCT06965452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Spinal angiography and embolization/ Embozene Microspheres is the first listed.
NCT06965452 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06965452 about?
NCT06965452 is a clinical study titled "Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy". This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
What is the current status of trial NCT06965452?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-08-12. Estimated completion is 2026-08-01.
What conditions does trial NCT06965452 study?
This clinical trial studies the following conditions: Pain, Osteoarthritis, Facet Joint Arthropathy.
What interventions are being tested in trial NCT06965452?
The interventions under investigation include: Spinal angiography and embolization/ Embozene Microspheres (DEVICE).
Who is sponsoring clinical trial NCT06965452?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06965452 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06965452's enrollment target sits among peer trials
40 282nd of 374 higher than 85 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Pain With Dementia
RECRUITING · NA
-
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI